In this study, we employ calcipotriol, a potent VDR agonist, to test its therapeutic effect in cholestasis, determine whether VDR can modulate NLRP3 to inhibit HSC activation and alleviate liver fibrosis and injury, and explore the underlying mechanism. The gene discussed is VDR; the disease is Hepatic fibrosis.